U.S. markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
28.51+0.20 (+0.71%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close28.31
Open28.00
Bid28.52 x 2200
Ask28.54 x 800
Day's Range27.87 - 28.73
52 Week Range12.30 - 29.65
Volume632,804
Avg. Volume940,062
Market Cap1.422B
Beta (5Y Monthly)1.31
PE Ratio (TTM)161.07
EPS (TTM)0.18
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-47% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference
    GlobeNewswire

    Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

    STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference on Wednesday, April 14, 2021 at 2:15 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis, primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin solution for injection. Difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT: Claire LaCagnina6 Degrees315-765-1462 clacagnina@6degreespr.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.janhavi.mohite@SternIR.com

  • Cara (CARA) Surges 14%: Is This an Indication of Further Gains?
    Zacks

    Cara (CARA) Surges 14%: Is This an Indication of Further Gains?

    Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

  • Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
    Zacks

    Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

    Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.